CPaaS Acceleration Alliance
Industry analysts and vendors examine market trends, new technologies, sales channels, and use cases propelling the CPaaS industry's growth
AMSTERDAM, NETHERLANDS / ACCESSWIRE / May 16, 2023 / The CPaaS Acceleration Alliance (CPaaSAA) announced today the release of its 2023 State of CPaaS Report. The report examines key factors propelling the CPaaS industry's growth to USD 100B by 2030. These factors include market trends, new technologies, new sales channels, and new use cases.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Key CPaaS use cases and market trends
This year's report is being distributed freely and was created in partnership with leading industry analysts and vendors. It extends beyond existing technical analyst reports by focusing on commercialization of CPaaS. Executives, product planners, and revenue leaders will find the following information in the report:
- The top enterprise markets driving CPaaS growth
- The top market and CPaaS trends that are creating demand
- The top go-to-market challenges facing CPaaS providers today, and how to overcome them
This report sets the tone for CPaaSAA thought leadership tracks in 2023. These tracks will include live expert panels, blogs, workshops, and podcasts covering:
- Selling to and enabling non-IT buyers & SMEs
- Moving beyond UCaaS and CCaaS with CPaaS
- Leveraging AI and other enabling technologies in communications
- Network API standardization and monetization
CPaaSAA is the global alliance for the CPaaS industry. Vendors, service providers, sales partners, industry experts, and media are working together through CPaaSAA to create mutual success and growth.
"This is an exciting time for CPaaS," says Rob Kurver, founding partner and visionary of CPaaSAA. "The CPaaS market will grow from USD 16B in 2022 to USD 100B in 2030. We feel this is truly the right place and the right time for the industry to come together for mutual success."
Managing partner Kevin Nethercott adds, "The industry response has been tremendous. CPaaSAA has added over 50 members in the last six months. We expect it to grow to over 100 members by the end of 2023. This is a testament to the value CPaaSAA brings to its members through expert panels, marketing relationships, global meetups, and the industry's first CPaaS-focused conference this September 18-20 in Amsterdam."
Finally, this year's report highlights significant opportunity for vendors and service providers to win new business. "CPaaS is the fastest growing segment of the communications industry," says Melissa Fremeijer-Holtz with global market intelligence firm, IDC. "We see growth in every market including Latin and North America, Asia Pacific, the Middle East and Africa. We also see growth across large enterprises, SMEs, and communication service providers."
Visit www.cpaasaa.com/state-of-cpaas to learn more and to download this year's State of CPaaS report for free.
About CPaaS Acceleration Alliance
CPaaS Acceleration Alliance (CPaaSAA) is accelerating growth and adoption of communications platforms. We bring together CPaaS platform and service providers, enablers, technology vendors, sales partners, advisory partners, industry experts and media to collaborate for mutual success and growth, building the strategies, partnerships and best practices that will power the CPaaS industry from $16B in 2022 to $100B+ by 2030.
CPaaSAA members include CPaaS providers, enablers, CCaaS & UCaaS providers, technology vendors, CSPs, investors, media, and analysts such as: Braidio, e& enterprise, EnableX, Radisys, Sippio, 2600Hz, CM.com, Crexendo, GMS, Luware, SpeechLogix, Arthur D Little, BICS, Content Guru, Creo Solutions, Enabld, Evan Kirstel, iotum, Kandy Communications (a Skyvera company), KeyBanc Mosaic, NTT Data, NUSO, Q Advisors, Sinch, STL Partners, Syniverse, TelcoBridges, TelecomsXchange, The Next Cloud, True North Advisory, VodafoneZiggo.
For more information, please visit www.cpaasaa.com.
Contact Information
Robert Galop
CMO
robert@cpaasaa.com
+31 97 010204663
SOURCE: CPaaS Acceleration Alliance
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/754557/CPaaS-Acceleration-Alliance-Releases-2023-State-of-CPaaS-Report-Forecasts-CPaaS-Market-Will-Grow-to-USD-100B-by-2030
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom